Sweden’s Omnio raises €2.9 million to advance its plasminogen-based therapy for hard-to-heal chronic wounds
Omnio, a Umeå-based BioTech startup, has raised an oversubscribed €2.9 million round from existing investors and shareholders to advance its plasminogen-based therapy for hard-to-heal chronic wounds toward clinical studies. This funding follows a €4.3 million financing round completed in spring 202
<p>Omnio, a Umeå-based BioTech startup, has raised an oversubscribed €2.9 million round from existing investors and shareholders to advance its plasminogen-based therapy for hard-to-heal chronic wounds toward clinical studies. This funding follows a €4.3 million financing round completed in spring 202</p>